|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM218 |
Gene summary for TMEM218 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM218 | Gene ID | 219854 |
| Gene name | transmembrane protein 218 | |
| Gene Alias | TMEM218 | |
| Cytomap | 11q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A2RU14 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 219854 | TMEM218 | LZE20T | Human | Esophagus | ESCC | 1.76e-02 | 1.52e-01 | 0.0662 |
| 219854 | TMEM218 | LZE24T | Human | Esophagus | ESCC | 1.73e-05 | 3.05e-01 | 0.0596 |
| 219854 | TMEM218 | P2T-E | Human | Esophagus | ESCC | 7.23e-09 | 2.07e-01 | 0.1177 |
| 219854 | TMEM218 | P4T-E | Human | Esophagus | ESCC | 2.71e-22 | 5.44e-01 | 0.1323 |
| 219854 | TMEM218 | P5T-E | Human | Esophagus | ESCC | 3.75e-06 | 1.96e-01 | 0.1327 |
| 219854 | TMEM218 | P8T-E | Human | Esophagus | ESCC | 1.34e-14 | 3.34e-01 | 0.0889 |
| 219854 | TMEM218 | P9T-E | Human | Esophagus | ESCC | 6.25e-11 | 2.59e-01 | 0.1131 |
| 219854 | TMEM218 | P10T-E | Human | Esophagus | ESCC | 6.04e-16 | 3.66e-01 | 0.116 |
| 219854 | TMEM218 | P11T-E | Human | Esophagus | ESCC | 8.65e-09 | 3.07e-01 | 0.1426 |
| 219854 | TMEM218 | P12T-E | Human | Esophagus | ESCC | 8.57e-20 | 2.94e-01 | 0.1122 |
| 219854 | TMEM218 | P15T-E | Human | Esophagus | ESCC | 3.27e-07 | 1.13e-01 | 0.1149 |
| 219854 | TMEM218 | P16T-E | Human | Esophagus | ESCC | 2.80e-18 | 3.59e-01 | 0.1153 |
| 219854 | TMEM218 | P17T-E | Human | Esophagus | ESCC | 2.88e-02 | 1.51e-01 | 0.1278 |
| 219854 | TMEM218 | P19T-E | Human | Esophagus | ESCC | 1.91e-05 | 3.49e-01 | 0.1662 |
| 219854 | TMEM218 | P20T-E | Human | Esophagus | ESCC | 1.04e-09 | 2.52e-01 | 0.1124 |
| 219854 | TMEM218 | P21T-E | Human | Esophagus | ESCC | 3.40e-31 | 5.96e-01 | 0.1617 |
| 219854 | TMEM218 | P22T-E | Human | Esophagus | ESCC | 4.24e-15 | 1.85e-01 | 0.1236 |
| 219854 | TMEM218 | P23T-E | Human | Esophagus | ESCC | 1.59e-11 | 2.48e-01 | 0.108 |
| 219854 | TMEM218 | P24T-E | Human | Esophagus | ESCC | 2.12e-08 | 1.45e-01 | 0.1287 |
| 219854 | TMEM218 | P26T-E | Human | Esophagus | ESCC | 1.76e-17 | 3.38e-01 | 0.1276 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM218 | insertion | In_Frame_Ins | novel | c.8_9insTAGTAATTT | p.Gly3_Thr4insSerAsnPhe | p.G3_T4insSNF | A2RU14 | protein_coding | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| TMEM218 | SNV | Missense_Mutation | c.167N>G | p.Leu56Arg | p.L56R | A2RU14 | protein_coding | deleterious(0) | possibly_damaging(0.681) | TCGA-AA-A01T-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| TMEM218 | SNV | Missense_Mutation | c.116N>T | p.Ser39Phe | p.S39F | A2RU14 | protein_coding | tolerated(0.1) | probably_damaging(0.997) | TCGA-DM-A1D9-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM218 | SNV | Missense_Mutation | c.115N>A | p.Ser39Thr | p.S39T | A2RU14 | protein_coding | tolerated(0.22) | probably_damaging(0.987) | TCGA-DM-A1D9-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM218 | insertion | Nonsense_Mutation | novel | c.260_261insCTGAA | p.Ser88Ter | p.S88* | A2RU14 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMEM218 | deletion | Frame_Shift_Del | c.73delC | p.Leu25CysfsTer24 | p.L25Cfs*24 | A2RU14 | protein_coding | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |||
| TMEM218 | SNV | Missense_Mutation | c.116N>A | p.Ser39Tyr | p.S39Y | A2RU14 | protein_coding | tolerated(0.1) | probably_damaging(0.997) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| TMEM218 | SNV | Missense_Mutation | rs763099953 | c.104N>T | p.Ala35Val | p.A35V | A2RU14 | protein_coding | tolerated(0.37) | benign(0) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM218 | SNV | Missense_Mutation | novel | c.148N>G | p.Ile50Val | p.I50V | A2RU14 | protein_coding | tolerated(0.26) | benign(0) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM218 | SNV | Missense_Mutation | novel | c.173N>A | p.Pro58Gln | p.P58Q | A2RU14 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CN-A498-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |